Phase 2 Parkinson's Disease Trial, Recruiting NCT03457493 Sponsor: University of Alabama at Birmingham Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 2 Parkinson's Disease Trial, Recruiting

NCT03457493
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must already be enrolled in one of two specific UAB Parkinson's disease research studies (ask the trial site which ones apply to you).
  • If you are a woman who could become pregnant, you must have a negative pregnancy test (urine or blood) within 2 days before the imaging scan. Women who have gone through menopause for at least 1 year, or have had a surgical procedure to prevent pregnancy, do not need this test.
  • You must have a specific genetic result (from a gene variant called rs6971) showing you are a "high affinity" or "mixed affinity" binder — this is determined by a genetic test (confirm with trial site).
  • You must be 30 years of age or older.
  • For one specific group (the UDALL 5-year Follow-Up group): you must have taken part in the original UDALL Baseline study, and your first scan must have been done no more than 6 years ago.

Who may not be able to join:

  • You do not meet the eligibility requirements for the related UAB Parkinson's disease research studies mentioned above.
  • You have a medical reason why you cannot safely have an MRI or PET scan.
  • Your Parkinson's disease or another health condition makes it too difficult for you to take part in the imaging (scanning) sessions.
  • Your genetic test result (rs6971) shows you are a "low affinity" binder for the tracer used in the scan.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jonathan McConathy, MD, University of Alabama at Birmingham

Phone: 205-996-7115

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
22 March 2018
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Comparison of TSPO-PET measures of neuroinflammation between PD patients and healthy controls.; Correlation of DPA-714-PET/MRI with demographics, clinical and biospecimen assessments from Neuroinflammation in PD study

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov